Cancer neoantigen: Boosting immunotherapy

Biomed Pharmacother. 2020 Nov:131:110640. doi: 10.1016/j.biopha.2020.110640. Epub 2020 Aug 21.

Abstract

Tumor neoantigen has a high degree of immunogenicity. As one of the emerging methods of tumor immunotherapy, the vaccine developed against it has served to clinical trials of various solid tumors, especially in the treatment of melanoma. Currently, a variety of immunotherapy methods have been applied to the treatment of the tumor. However, other therapeutic methods have the disadvantages of low specificity and prominent side effects. Treatments require tumor antigen with higher immunogenicity as the target of immune attack. This review will recommend the identification of neoantigen, the influencing factors of neoantigen, and the application of personalized vaccines for neoantigen in metastatic tumors such as malignant melanoma.

Keywords: Immunotherapy; Melanoma; Neoantigen; Personalized vaccine; Tumor mutational burden.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, Neoplasm* / genetics
  • Antigens, Neoplasm* / immunology
  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / genetics
  • Cancer Vaccines / immunology
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy / trends
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Precision Medicine / methods*
  • Precision Medicine / trends

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines